Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran.

导出 OA

翻译打印收藏纠错

作者： Abdosaleh,Jafari ^[1] ; Sedighe Sadat,Tabatabaei Far ^[2] ; Mehdi,Dehghani ^[3] ; Ramin,Ravangard ^[1]

作者单位： Health Human Resources Research Centre, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. ^[1] Student Research Committee, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. ^[2] Department of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ^[3]

关键词 Bevacizumab Cetuximab FOLFOX6 colorectal cancer cost-effectiveness

主题词人类(Humans);伊朗(Iran);费用效益分析(Cost-Benefit Analysis);结直肠肿瘤(Colorectal Neoplasms)

DOI 10.1177/10732748231180679

PMID 37314727

发布时间 2023-07-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer control

10732748231180679页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran.

Cancer control

相似文献

Cancer control

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran.

Cancer control

相似文献

Cancer control

相关期刊

检索历史清除